Joseph R. Garlich

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Joseph R. Garlich, Pradip De, Nandini Dey et al. · Cancer Research · 2008 · 281 citations

Pharmacy, Medicinal Chemistry, Pharmacology +15

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Daruka Mahadevan, E. Gabriela Chiorean, Wayne B. Harris et al. · European Journal of Cancer · 2012 · 134 citations

Medicine, Oncology, Pharmacology +11

Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis

Forest H. Andrews, Alok R. Singh, Shweta Joshi et al. · Proceedings of the National Academy of Sciences · 2017 · 119 citations · Full text

Medicine, Cancer Biology, Oncology +16

Recent advances in the chemistry of spinosyns

Gary D. Crouse, Thomas C. Sparks, Joseph R. Schoonover et al. · Pest Management Science · 2001 · 98 citations

Agriculture, Entomology, Biological Control +13

Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.

John E. Bayouth, Daniel J. Macey, Leela P. Kasi et al. · PubMed · 1995 · 73 citations

Medicine, Pharmacokinetics, Pharmacology +15